Cardiac amyloidosis

11 trials 3 recruiting MedDRA PT
11 Registered trials
3 Recruiting
5 Unique sponsors
7 Unique IMPs
8 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
N Neurology/Psychiatry (ATC N) 5
V Various (ATC V) 3
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
siRNA 2 substances
Monoclonal antibody 1 substance
SGLT2 inhibitor 1 substance
Phase III: 9 Phase II/III: 1 Phase II: 2

Filter these 11 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 11 trials

Phase III

9 trials
  • Alexion Pharmaceuticals Inc. Commercial
    ANSELAMIMAB
    2022-503072-84-00 8 countries 2021 n=83 Orphan
    Ended
  • Alexion Pharmaceuticals Inc. Commercial
    ANSELAMIMAB
    2022-503073-11-00 9 countries 2021 n=56 Orphan
    Ended
  • Alnylam Pharmaceuticals Inc. Commercial
    PATISIRAN
    2023-508364-29-00 8 countries 2019 n=79 Orphan
    Ended
  • Alnylam Pharmaceuticals Inc. Commercial
    PATISIRAN; VUTRISIRAN
    2023-508365-33-00 7 countries 2019 n=44 Orphan
    Ended
  • Alnylam Pharmaceuticals Inc. Commercial
    VUTRISIRAN
    2024-518318-25-00 16 countries 2020 n=441 Orphan
    Ended
  • Alnylam Pharmaceuticals Inc. Commercial
    VUTRISIRAN
    2024-518343-38-00 11 countries 2025 n=208 Orphan
    Ended
  • Lantheus Germany GmbH Commercial
    FLORBETABEN (18F)
    2022-500186-27-00 2 countries 2023 n=169
    Ended
  • Fondazione Toscana Gabriele Monasterio Academic
    FLORBETABEN (18F)
    2024-517942-33-03 1 country 2023 n=150
    Recruiting
  • Alnylam Pharmaceuticals Inc. Academic
    PATISIRAN; VUTRISIRAN
    2023-508365-33-00 7 countries 2019 n=44 Orphan
    Ended

Phase II/III

1 trial
  • Intellia Therapeutics Inc. Commercial
    ZICLUMERAN, SINGLE GUIDE RNA TARGETING THE HUMAN TTR GENE
    2023-507385-11-00 2 countries 2024 n=15 Orphan
    Recruiting

Phase II

2 trials
  • Fondazione Toscana Gabriele Monasterio Academic
    DAPAGLIFLOZIN
    2023-504041-31-00 1 country 2023 n=50
    Recruiting
  • Fondazione Toscana Gabriele Monasterio Academic
    FLUTEMETAMOL (18F)
    2024-517971-19-01 1 country 2023 n=45
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Alnylam Pharmaceuticals Inc. Commercial 5 Phase III 0
Fondazione Toscana Gabriele Monasterio Academic 3 Phase II, Phase III 2
Alexion Pharmaceuticals Inc. Commercial 2 Phase III 0
Intellia Therapeutics Inc. Commercial 1 Phase II/III 1
Lantheus Germany GmbH Commercial 1 Phase III 0
New trials by year
2019
3
2020
1
2021
2
2023
4
2024
1
2025
1
← All indication landscapes